Key facts
- Notable investors include Shenzhen Capital Group, Puhua Capital, Yinxinggu Capital, Ruiying Asset Management, Beijing Shengshi Hongming Investment Fund Management — 14 tracked in total.
- Status: In IPO Registration.
Investors
14+- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Biosun Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosun Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosun Pharma
Developer of pharmaceuticals designed for oncology, autoimmunity, inflammation field. The company focuses on molecular targeting and antibody drug development, enabling doctors to provide with advanced drugs with patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- biosunpharma.com/
- Ownership
- In IPO Registration
Biosun Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosun Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosun Pharma in its N-PORT filings yet. We sweep new filings monthly.